A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2017
At a glance
- Drugs Seviteronel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Innocrin Pharmaceuticals; Viamet Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 02 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.
- 02 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2017.